A Case of Adult Hepatoblastoma
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Carcinoid) Tumours Gastroenteropancreatic
Downloaded from gut.bmjjournals.com on 8 September 2005 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, R Thakker, S Aylwin, D Breen, K Britton, K Buchanan, P Corrie, A Gillams, V Lewington, D McCance, K Meeran, A Watkinson and on behalf of UKNETwork for neuroendocrine tumours Gut 2005;54;1-16 doi:10.1136/gut.2004.053314 Updated information and services can be found at: http://gut.bmjjournals.com/cgi/content/full/54/suppl_4/iv1 These include: References This article cites 201 articles, 41 of which can be accessed free at: http://gut.bmjjournals.com/cgi/content/full/54/suppl_4/iv1#BIBL Rapid responses You can respond to this article at: http://gut.bmjjournals.com/cgi/eletter-submit/54/suppl_4/iv1 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Topic collections Articles on similar topics can be found in the following collections Stomach and duodenum (510 articles) Pancreas and biliary tract (332 articles) Guidelines (374 articles) Cancer: gastroenterological (1043 articles) Liver, including hepatitis (800 articles) Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Gut go to: http://www.bmjjournals.com/subscriptions/ Downloaded from gut.bmjjournals.com on 8 September 2005 iv1 GUIDELINES Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours J K Ramage*, A H G Davies*, J ArdillÀ, N BaxÀ, M CaplinÀ, A GrossmanÀ, R HawkinsÀ, A M McNicolÀ, N ReedÀ, R Sutton`, R ThakkerÀ, S Aylwin`, D Breen`, K Britton`, K Buchanan`, P Corrie`, A Gillams`, V Lewington`, D McCance`, K Meeran`, A Watkinson`, on behalf of UKNETwork for neuroendocrine tumours .............................................................................................................................. -
What You Should Know About Familial Adenomatous Polyposis (FAP)
What you should know about Familial Adenomatous Polyposis (FAP) FAP is a very rare condition that accounts for about 1% of new cases of colorectal cancer. People with FAP typically develop hundreds to thousands of polyps (adenomas) in their colon and rectum by age 30-40. Polyps may also develop in the stomach and small intestine. Individuals with FAP can develop non-cancerous cysts on the skin (epidermoid cysts), especially on the scalp. Besides having an increased risk for colon polyps and cysts, individuals with FAP are also more likely to develop sebaceous cysts, osetomas (benign bone tumors) of the jaw, impacted teeth, extra teeth, CHRPE (multiple areas of pigmentation in the retina in the eye) and desmoid disease. Some individuals have milder form of FAP, called attenuated FAP (AFAP), and develop an average of 20 polyps at a later age. The risk for cancer associated with FAP If left untreated, the polyps in the colon and rectum will develop in to cancer, usually before age 50. Individuals with FAP also have an increased risk for stomach cancer, papillary thyroid cancer, periampullary carcinoma, hepatoblastoma (in childhood), and brain tumors. The risks to family members FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. Approximately 1/3 of people with FAP do not have family history of the disease, and thus have a new mutation. FAP is inherited in a dominant fashion. Children of a person with an APC mutation have a 50% risk to inherit the mutation. Brothers, sisters, and parents of individuals with FAP should also be checked to see if they have an APC mutation. -
Cholangiocarcinoma 2020: the Next Horizon in Mechanisms and Management
CONSENSUS STATEMENT Cholangiocarcinoma 2020: the next horizon in mechanisms and management Jesus M. Banales 1,2,3 ✉ , Jose J. G. Marin 2,4, Angela Lamarca 5,6, Pedro M. Rodrigues 1, Shahid A. Khan7, Lewis R. Roberts 8, Vincenzo Cardinale9, Guido Carpino 10, Jesper B. Andersen 11, Chiara Braconi 12, Diego F. Calvisi13, Maria J. Perugorria1,2, Luca Fabris 14,15, Luke Boulter 16, Rocio I. R. Macias 2,4, Eugenio Gaudio17, Domenico Alvaro18, Sergio A. Gradilone19, Mario Strazzabosco 14,15, Marco Marzioni20, Cédric Coulouarn21, Laura Fouassier 22, Chiara Raggi23, Pietro Invernizzi 24, Joachim C. Mertens25, Anja Moncsek25, Sumera Rizvi8, Julie Heimbach26, Bas Groot Koerkamp 27, Jordi Bruix2,28, Alejandro Forner 2,28, John Bridgewater 29, Juan W. Valle 5,6 and Gregory J. Gores 8 Abstract | Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. -
Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach
International Journal of Molecular Sciences Review Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach Isabella Lurje 1,† , Zoltan Czigany 1,† , Jan Bednarsch 1, Christoph Roderburg 2,3, Peter Isfort 4, Ulf Peter Neumann 1,5 and Georg Lurje 1,* 1 Department of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] (I.L.); [email protected] (Z.C.); [email protected] (J.B.); [email protected] (U.P.N.) 2 Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] 3 Department of Gastroenterology/Hepatology, Campus Virchow Klinikum and Charité Mitte, Charité University Medicine Berlin, 13353 Berlin, Germany 4 Department for Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] 5 Department of Surgery, Maastricht University Medical Centre (MUMC), 6229 ET Maastricht, The Netherlands * Correspondence: [email protected] † Both authors contributed equally to this work. Received: 9 March 2019; Accepted: 21 March 2019; Published: 22 March 2019 Abstract: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its mortality is third among all solid tumors, behind carcinomas of the lung and the colon. Despite continuous advancements in the management of this disease, the prognosis for HCC remains inferior compared to other tumor entities. While orthotopic liver transplantation (OLT) and surgical resection are the only two curative treatment options, OLT remains the best treatment strategy as it not only removes the tumor but cures the underlying liver disease. As the applicability of OLT is nowadays limited by organ shortage, major liver resections—even in patients with underlying chronic liver disease—are adopted increasingly into clinical practice. -
Mixed Hepatoblastoma in the Adult: Case Report and Review of the Literature
J Clin Pathol: first published as 10.1136/jcp.33.11.1058 on 1 November 1980. Downloaded from J Clin Pathol 1980;33:1058-1063 Mixed hepatoblastoma in the adult: case report and review of the literature RP HONAN AND MT HAQQANI From the Department of Pathology, Walton Hospital, Rice Lane, Liverpool L9 JAE, UK SUMMARY A case of mixed hepatoblastoma in a woman is described. A survey of the English literature reveals 13 cases acceptable as mixed hepatoblastoma; these have been described and published under a variety of names. Difficulties in nomenclature and the histology of these cases are discussed. Diagnosis depends on the identification of both malignant mesenchymal and malignant epithelial elements. The former include myxoid connective tissue resembling primitive mesenchyme and areas resembling adult fibrosarcoma. Mature fibrous tissue with calcification and bone for- mation may be seen. Epithelial areas show tissue resembling fetal liver, poorly differentiated epithelial cells, and/or areas of adenocarcinoma. The current view on histogenesis is also given. Most hepatoblastomas occur in children under the mixedtumour,6carcino-osteochondromyxosarcoma,5 copyright. age of 2 years.' Hepatoblastoma in adults is ex- and rhabdomyosarcohepatoma.7 tremely rare, and the prognosis is much worse than in the mixed hepatoblastoma of childhood. Case report The literature of mixed hepatoblastoma in adults has until recently been confused, and the true inci- CLINICAL PRESENTATION dence of the tumour obscured, owing to the various A Chinese woman aged 27 had been resident in names used by different authors to describe their England for eight years. She gave a history of cases. The commonest pseudonym is 'mixed malig- 18 months' intermittent right-sided chest pain http://jcp.bmj.com/ nant tumour',2-4 an ambivalent term which merely and upper abdominal discomfort. -
Case Report Metastasis of Pancreatic Cancer Within Primary Colon Cancer by Overtaking the Stromal Microenvironment
Int J Clin Exp Pathol 2018;11(6):3141-3146 www.ijcep.com /ISSN:1936-2625/IJCEP0075771 Case Report Metastasis of pancreatic cancer within primary colon cancer by overtaking the stromal microenvironment Takeo Nakaya1, Hisashi Oshiro1, Takumi Saito2, Yasunaru Sakuma2, Hisanaga Horie2, Naohiro Sata2, Akira Tanaka1 Departments of 1Pathology, 2Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan Received March 10, 2018; Accepted April 15, 2018; Epub June 1, 2018; Published June 15, 2018 Abstract: We report a unique case of a 74-old man, who presented with double cancers, showing metastasis of pancreatic cancer to colon cancer. Histopathological examination after surgery revealed that the patient had as- cending colon cancer, which metastasized to the liver (pT4N0M1), as well as pancreatic cancer (pT2N1M1) that metastasized to the most invasive portion of the colon cancer, namely the serosal to subserosal layers. Although the mechanisms for this scenario have yet to be elucidated, we speculate that the metastatic pancreatic carcinoma overtook the stromal microenvironment of the colon cancer. Namely, the cancer microenvironment enriched by can- cer-associated fibroblasts, which supported the colon cancer, might be suitable for the invasion and engraftment by pancreatic carcinoma. The similarity of histological appearance might make it difficult to distinguish metastatic pancreatic carcinoma within colon cancer. Furthermore, the metastasis of pancreatic carcinoma in colon carcinoma might be more common, despite it not having been previously reported. Keywords: Cancer metastasis, metastatic pancreatic cancer, colon cancer, double cancer, tumor microenviron- ment Introduction Case report Prevention and control of cancer metastasis is Clinical history one of the most important problems in cancer care [1-4]. -
PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information. -
Radiation-Associated Synovial Sarcoma
Radiation-Associated Synovial Sarcoma: Clinicopathologic and Molecular Analysis of Two Cases Jean-François Egger, M.D., Jean-Michel Coindre, M.D., Jean Benhattar, Ph.D., Philippe Coucke, M.D., Louis Guillou, M.D. University Institute of Pathology (J-FE, JB, LG) and Department of Radiooncology, University Hospital (PC), Lausanne, Switzerland; Bergonié Institute and University of Bordeaux II (J-MC), Bordeaux, France region, or viscera (1, 2). SS bears the t(X;18) (SYT- Development of a soft-tissue sarcoma is an infre- SSX) reciprocal translocation that seems to be spe- quent but well-known long-term complication of cific for this tumor type and can be routinely de- radiotherapy. Malignant fibrous histiocytomas, ex- tected in paraffin-embedded tissue using the traskeletal osteosarcomas, fibrosarcomas, malig- reverse transcriptase–polymerase chain reaction nant peripheral nerve sheath tumors, and angiosar- (RT-PCR; 3–6). Radiation-associated sarcomas are comas are most frequently encountered. Radiation- an infrequent but well-known long-term complica- associated synovial sarcomas are exceptional. We tion of radiotherapy (7–16). They occur in about report the clinicopathologic, immunohistochemi- 1/1000 patients who have undergone radiation cal, and molecular features of two radiation- therapy (7–11). Radiation-associated sarcomas are associated synovial sarcomas. One tumor developed defined as sarcomas arising in a previously irradi- in a 42-year-old female 17 years after external irra- ated field after a latency period of Ն2 years (12). diation was given for breast carcinoma; the other They usually show a more aggressive clinical course occurred in a 34-year-old female who was irradiated associated with shortened patient survival as com- at the age of 7 years for a nonneoplastic condition of pared with sporadic sarcomas (9–12, 14). -
Morphological and Immunohistochemical Characteristics of Surgically Removed Paediatric Renal Tumours in Latvia (1997–2010)
DOI: 10.2478/v10163-012-0008-6 ACTA CHIRURGICA LATVIENSIS • 2011 (11) ORIGINAL ARTICLE Morphological and Immunohistochemical Characteristics of Surgically Removed Paediatric Renal Tumours in Latvia (1997–2010) Ivanda Franckeviča*,**, Regīna Kleina*, Ivars Melderis** *Riga Stradins University, Riga, Latvia **Children’s Clinical University Hospital, Riga, Latvia Summary Introduction. Paediatric renal tumours represent 7% of all childhood malignancies. The variable appearances of the tumours and their rarity make them especially challenging group of lesions for the paediatric pathologist. In Latvia diagnostics and treatment of childhood malignancies is concentrated in Children’s Clinical University Hospital. Microscopic evaluation of them is realised in Pathology office of this hospital. Aim of the study is to analyze morphologic spectrum of children kidney tumours in Latvia and to characterise them from modern positions with wide range of immunohistochemical markers using morphological material of Pathology bureau of Children’s Clinical University Hospital. Materials and methods. We have analyzed surgically removed primary renal tumours in Children Clinical University Hospital from the year 1997 till 2010. Samples were fixed in 10% formalin fluid, imbedded in paraffin and haematoxylin-eosin stained slides were re-examined. Immunohistochemical re-investigation was made in 65.91% of cases. For differential diagnostic purposes were used antibodies for the detection of bcl-2, CD34, EMA, actin, desmin, vimentin, CKAE1/AE3, CK7, Ki67, LCA, WT1, CD99, NSE, chromogranin, synaptophyzin, S100, myoglobin, miogenin, MyoD1 (DakoCytomation) and INI1 protein (Santa Cruz Biotechnology). Results. During the revised period there were diagnosed 44 renal tumours. Accordingly of morphological examination data neoplasms were divided: 1) nephroblastoma – 75%, 2) clear cell sarcoma – 2.27%, 3) rhabdoid tumour – 4.55%, 4) angiomyolipoma – 4.55%, 5) embrional rhabdomyosarcoma – 2.27%, 6) mesoblastic nephroma – 4.55%, 7) multicystic nephroma – 4.55%, 8) angiosarcoma – 2.27%. -
Dermatofibrosarcoma Protuberans of the Parotid Gland -A Case Report
The Korean Journal of Pathology 2004; 38: 276-9 Dermatofibrosarcoma Protuberans of the Parotid Gland -A Case Report - Ok-Jun Lee∙David Y. Pi∙ Dermatofibrosarcoma protuberans (DFSP) typically presents during the early or mid-adult life, Daniel H. Jo∙Kyung-Ja Cho and the most common site of origin is the skin on the trunk and proximal extremities. DFSP of Sang Yoon Kim1∙Jae Y. Ro the parotid gland is extremely rare and only one case has been reported in the literature. We present here a case of a 30-year-old woman with DFSP occurring in the parotid gland, and we Departments of Pathology and discuss the differential diagnosis. The patient is alive and doing well one year after her operation. 1Otolaryngology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Received : January 27, 2004 Accepted : July 5, 2004 Corresponding Author Jae Y. Ro, M.D. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Korea Tel: 02-3010-4550 Fax: 02-472-7898 E-mail: [email protected] Key Words : Dermatofibrosarcoma Protuberans-Parotid Gland Epithelial tumors make up the majority of salivary gland neo- CASE REPORT plasms, while mesenchymal tumors of this organ are uncommon. Dermatofibrosarcoma protuberans (DFSP) of the salivary gland A 30-year-old woman came to the Otolaryngology Clinic at is exremely rare and only one case has been reported in the parotid the Asan Medical Center with a 2-year history of a slowly enlarg- gland.1 ing mass inferior to the left angle of the mandible. -
Pediatric Abdominal Masses
Pediatric Abdominal Masses Andrew Phelps MD Assistant Professor of Pediatric Radiology UCSF Benioff Children's Hospital No Disclosures Take Home Message All you need to remember are the 5 common masses that shouldn’t go to pathology: 1. Infection 2. Adrenal hemorrhage 3. Renal angiomyolipoma 4. Ovarian torsion 5. Liver hemangioma Keys to (Differential) Diagnosis 1. Location? 2. Age? 3. Cystic? OUTLINE 1. Kidney 2. Adrenal 3. Pelvis 4. Liver OUTLINE 1. Kidney 2. Adrenal 3. Pelvis 4. Liver Renal Tumor Mimic – Any Age Infection (Pyelonephritis) Don’t send to pathology! Renal Tumor Mimic – Any Age Abscess Don’t send to pathology! Peds Renal Tumors Infant: 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Child: 1) Wilm's tumor 2) lymphoma 3) angiomyolipoma 4) clear cell sarcoma 5) multilocular cystic nephroma Teen: 1) renal cell carcinoma 2) renal medullary carcinoma Peds Renal Tumors Infant: 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Child: 1) Wilm's tumor 2) lymphoma 3) angiomyolipoma 4) clear cell sarcoma 5) multilocular cystic nephroma Teen: 1) renal cell carcinoma 2) renal medullary carcinoma Renal Tumors - Infant 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Renal Tumors - Infant 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor - Most common - Can’t distinguish from congenital Wilms. Renal Tumors - Infant 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Look for Multiple biggest or diffuse and masses. ugliest. Renal Tumors - Infant 1) mesoblastic -
NY-ESO-1 (CTAG1B) Expression in Mesenchymal Tumors
Modern Pathology (2015) 28, 587–595 & 2015 USCAP, Inc. All rights reserved 0893-3952/15 $32.00 587 NY-ESO-1 (CTAG1B) expression in mesenchymal tumors Makoto Endo1,2,7, Marieke A de Graaff3,7, Davis R Ingram4, Simin Lim1, Dina C Lev4, Inge H Briaire-de Bruijn3, Neeta Somaiah5, Judith VMG Bove´e3, Alexander J Lazar6 and Torsten O Nielsen1 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; 2Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan; 3Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA and 6Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions.